Function ‐ not measured · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Harms · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache · rotator cuff disease
It is very uncertain whether summary of findings: 5 mg/day changes headache ( compared with injection with corticosteroid and anaesthetic (very low certainty).
1 finding from 1 review
Injection site pain · rotator cuff disease
It is very uncertain whether summary of findings: 5 mg/day changes injection site pain ( compared with injection with corticosteroid and anaesthetic (very low certainty).
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · rotator cuff disease
1 finding from 1 review
Symptom free ( · rotator cuff disease
It is very uncertain whether summary of findings: 5 mg/day changes symptom free ( compared with placebo (very low certainty).
1 finding from 1 review
Function ‐ not measured · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Harms · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache ‐ not reported4 · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (5 mg/day/6 months) showed no clear difference in relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in treatment failure Need for additional treatment compared with SCS treatment (moderate certainty).
1 finding from 1 review
Relapse New acute exacerbation or COPD‐related admission · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in relapse New acute exacerbation or COPD‐related admission compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effects Gastrointestinal tract bleeding, symptomatic… compared with SCS treatment (low certainty).
1 finding from 1 review
All‐cause mortality · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in mortality compared with SCS treatment (moderate certainty).
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
QoL · exacerbations of COPD
1 finding from 1 review
Number of infants with a caries increment · Infants/young children (primary teeth; baseline about 1 to 3 years)
Xylitol sucking tablets (1 g/day) showed no clear difference in number of infants with a caries increment compared with no treatment; GRADE not reported.
1 finding from 1 review